





# **Unsaturated Iron-Binding Capacity**

#### **Order information**

COBAS INTEGRA®	100 Tests	Cat. No. 20737631 322
Unsaturated Iron-Binding	System-ID 07 3763 1	
Calibrator f.a.s.	$12 \times 3 \text{ mL}$	Cat. No. 10759350 190
Calibrator f.a.s. (for USA)	$12 \times 3 \text{ mL}$	Cat. No. 10759350 360
		System-ID 07 3718 6
Precinorm® U	$20 \times 5 \text{ mL}$	Cat. No. 10171743 122
		System-ID 07 7997 0
Precinorm* U plus	$10 \times 3 \text{ mL}$	Cat. No. 12149435 122
		System-ID 07 7999 7
Precipath* U plus	$10 \times 3 \text{ mL}$	Cat. No. 12149443 122
		System-ID 07 8000 6

Indicates analyzer(s) on which cassette can be used

COBAS	COBAS	COBAS
INTEGRA	INTEGRA	INTEGRA
400/400 plus	700	800
•	•	•

#### Intended use

The COBAS INTEGRA Unsaturated Iron-Binding Capacity cassette (UIBC) contains an in vitro diagnostic reagent system intended for use on COBAS INTEGRA systems for the quantitative determination of the unsaturated iron-binding capacity in serum and plasma (test UIBC, 0-063 on COBAS INTEGRA 700/800 systems, 0-463 on COBAS INTEGRA 400/400 plus systems).

# Summary<sup>1,2,3</sup>

The prosthetic group of hemoglobin is the iron complex of protoporphyrin IX (heme) in which the centrally located iron atom acts as a stabilizer of oxyhemoglobin. Numerous enzymes and coenzymes require iron, e.g. peroxidases, catalases, cytochromes (which are also heme proteins), many of the enzymes of the Krebs cycle, and monoamine oxidase (which is involved in neurotransmission).

The total iron content of the body is about 3 to 3.5 g. Of this amount about 2.5 g is contained in erythrocytes or their precursors in the bone marrow. Plasma contains only about 2.5 mg of iron. Iron is transported as Fe(III) bound to the plasma protein apotransferrin. The apotransferrin-Fe(III) complex is called transferrin. Normally only about one third of the iron-binding sites of transferrin are occupied by Fe(III). The additional amount of iron that can be bound is the unsaturated (or latent) iron-binding capacity (UIBC). The sum of the serum iron and UIBC represents total iron-binding capacity (TIBC). TIBC is a measurement for the maximum iron concentration that transferrin can bind.

The serum TIBC varies in disorders of iron metabolism. In iron-deficiency anemia the TIBC is elevated and the transferrin saturation is lowered to 15% or less. Low serum iron associated with low TIBC is characteristic of the anemia of chronic disorders, malignant tumors, and infections.

# **Test principle**

Direct determination with FerroZine.4,5

	Alkaline Buffer	
Fe(II) + transferrin		transferrin-Fe(III) +
		Fe(II) (excess)

Fe(II) (excess) + 3 FerroZine Fe(II)-(FerroZine)3 The color intensity is directly proportional to the unbound excess iron concentration and indirectly proportional to the unsaturated iron-binding capacity. It is determined by measuring the increase in absorbance at 552 nm.

#### Reagents - working solutions

Saturating reagent in vial B (liquid). R2 = SR FerroZine in vial C (liquid).

# Active ingredients

Components	Concentrations			
	R1	SR	Test	
TRIS	375		150	mmol/L
Ferrous chloride	62		25	μmol/L
Sodium hydrogen				
carbonate	75		30	mmol/L
FerroZine		20	2.5	mmol/L
Hydroxylamine		160	20	mmol/L
Sodium azide	0.02		0.01	%
pН	8.4	2.5	8.4	

Reagent R1 contains a nonreactive stabilizer. Please see cassette label for reagent filling volumes.

### **Precautions and warnings**

Pay attention to all precautions and warnings listed in Chapter 1, Introduction.

This kit contains components classified as follows according to the European Directive 99/44/EC:

×	Xi	Irritar
-	/ <b>XI</b>	minta

R 43 May cause sensitization by skin contact.

S 24 Avoid contact with the skin. Wear suitable gloves.

Contact phone: all countries: +49-621-7590,

USA: +1-800-428-2336

# Reagent handling

Ready for use.

Substrates



# INTEGRA 400/700/800

# Storage and stability

Shelf life at 2 to 8°C See expiration date on cassette COBAS INTEGRA 400/400 plus analyzers On-board in use at 10 to 15°C 2 weeks COBAS INTEGRA 700/800 analyzers On-board in use at 8°C 8 weeks

# Specimen collection and preparation

For specimen collection and preparation, only use suitable tubes or collection containers.

Only the specimens listed below were tested and found acceptable. Serum (free from hemolysis and lipemia).

Plasma (free from hemolysis and lipemia): Li-heparin plasma.

Do not use EDTA, oxalate, or citrate plasma, since they bind iron ions, preventing their reaction with the chromogen. Specimens should be collected in the morning to avoid low results due to diurnal variation.

When processing samples in primary tubes, follow the instructions of the tube manufacturer.

Stability:6 4 days at 15-25°C 7 days at 4°C

Centrifuge samples containing precipitates before performing the assay.

#### **Materials provided**

See "Reagents - working solutions" section for reagents.

#### Assav

For optimal performance of the assay follow the directions given in this document for the analyzer concerned. Refer to the appropriate operator manual for analyzer-specific assay instructions.

# Application for serum and plasma

# COBAS INTEGRA 400/400 plus test definition

Measuring mode Absorbance Abs. calculation mode Endpoint R1-S-SR Reaction mode Reaction direction Increase Wavelength A/B 552/629 nm Calc. first/last 33/64

Test range 0-125 µmol/L (0-700 µg/dL)

Postdilution factor No Unit umol/L

# **Pipetting parameters**

		Diluent (H <sub>2</sub> O)
R1	80 μL	30 μL
Sample	30 μL	20 μL
SR	25 μL	15 μL
Total volume	200 μL	

# COBAS INTEGRA 700/800 test definition

Absorbance Measuring mode Abs. calculation mode Endpoint R1-S-SR Reaction mode Increase Reaction direction 552/629 nm Wavelength A/B Calc. first/last 43/97

0-125 µmol/L (0-700 µg/dL) Test range

Postdilution factor No Unit μmol/L

### **Pipetting parameters**

		Diluent (H <sub>2</sub> O)
R1	80 μL	30 μL
Sample	30 μL	20 μL
SR	25 μL	15 μL
Total volume	200 uL	

### Calibration

Calibrator Calibrator f.a.s.

Use deionized water as zero

calibrator.

Calibration mode Linear regression Calibration replicate Duplicate recommended

Calibration interval Each lot and as required following

quality control procedures

Traceability: This method has been standardized against a primary reference material (weighed in purified material) through iron.<sup>7</sup>

### **Quality control**

Reference range Precinorm U or Precinorm U plus Pathological range Precipath U plus Control interval 24 hours recommended Control sequence User defined Control after calibration Recommended

#### Calculation

COBAS INTEGRA analyzers automatically calculate the analyte concentration of each sample. For more details, please refer to Chapter 7, Data Analysis, User Manual (COBAS INTEGRA 700 analyzer), or to Data Analysis in the Online Help (COBAS INTEGRA 400/400 plus/800 analyzers).

Conversion factor:  $\mu mol/L \times 5.587 = \mu g/dL$ 

# **Limitations - interference**

If the patient's serum iron exceeds the binding capacity of the transferrin, a negative UIBC value results. Criterion: Recovery within ±10% of initial value. Serum, plasma

Hemolysis Avoid hemolyzed specimens. Hemoglobin

> levels higher than 0.06 mmol/L (1.0 g/L) increase the apparent UIBC value

significantly.

No significant interference. Icterus

Lipemia No significant interference up to an

Intralipid level of 200 mg/dL. Lipemic specimens may cause negative values and/or high absorbance flagging. Dilute the sample with NaCl 0.9% and rerun the assay. Calculate the result with the appropriate

dilution factor.

Anticoagulants Complexing anticoagulants such as EDTA, oxalate, and citrate must not be used.

> Of the drugs tested in vitro, methyldopa and oxytetracycline cause artificially high UIBC values at the tested drug level. Refer to

Chapter 1, Introduction, for a list of tested drugs and their concentration.

Pathologically high levels of albumin

(7 g/dL) decrease the apparent UIBC value

In very rare cases gammopathy, in particular type IgM (Waldenström's macroglobulinemia), may cause unreliable results.

Drugs

Other

For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination and other findings.

#### **Expected values**

Adults: 20-62 µmol/L (112-346 µg/dL) Each laboratory should investigate the transferability of the expected values to its own patient population and if necessary determine its own reference ranges.

#### Specific performance data<sup>7</sup>

Representative performance data on COBAS INTEGRA analyzers are given below. Results obtained in individual laboratories may differ.

#### Precision

Reproducibility was determined using human samples and controls in an internal protocol (within run n=20), between run n=20). The following results were obtained:

	Level 1	Level 2
Mean	25.0 μmol/L	43.4 μmol/L
	$(140 \mu g/dL)$	(242 µg/dL)
CV within run	1.6%	0.8%
CV between run	1.7%	1.2%

### Analytical sensitivity (lower detection limit)

4.2 µmol/L (23.5 µg/dL)

The detection limit represents the lowest measurable analyte level that can be distinguished from zero. It is calculated as the value lying three standard deviations above that of a zero sample (zero sample + 3 SD, within run precision, n = 30).

# **Method comparison**

UIBC values for human serum and plasma samples obtained on a COBAS INTEGRA 700 analyzer with the COBAS INTEGRA Unsaturated Iron-Binding Capacity cassette were compared to those determined with reagents for UIBC on a COBAS MIRA system and a commercially available alternative clinical chemistry system. Samples were measured in duplicate. Sample size (n) represents all replicates.

Values ranged from 0.2 to 81.5  $\mu$ mol/L (1.1 to 455.2  $\mu$ g/dL).

		COBAS MIRA	Alternative
		system	system
Sample size	(n)	238	230
Corr. coefficient	(r)	0.988	0.996
	$(r_s)$	0.979	0.994
Lin. regression	y	= 1.06 <i>x</i> - 1.1 μmol/L	$y = 0.93x + 1.7 \mu\text{mol/L}$
Passing/Bablok	<i>y</i> :	$= 1.08x + 1.0 \mu mol/I$	$y = 0.93x + 1.6 \mu\text{mol/L}$

#### References

- Fairbanks VF, Klee GG. Biochemical aspects of hematology. In: Tietz NW, ed. Fundamentals of Clinical Chemistry.
  3rd ed. Philadelphia: WB Saunders 1987:789-824.
- Bauer JD. Hemoglobin, porphyrin, and iron metabolism. In: Kaplan LA, Pesce AJ, eds. Clinical Chemistry, theory, analysis, and correlation. St. Louis: Mosby Company 1984:611-655.
- Lauber K, Peheim E, Perritaz R, Urbinelli R, Rietz P. Latente Eisenbindungskapazität und andere Eisenparameter im Plasma. GIT Labor Medizin 1991;14:95-96.
- 4. Stookey LL. FerroZine a new spectrophotometric reagent for iron. Anal Chem 1970;42:779-781.
- Persijn JP, Van der Slik W, Riethorst A. Determination of serum iron and latent iron-binding capacity (LIBC). Clin Chim Acta 1971;35:91-98.
- Weissman N, Pileggi VJ. Inorganic ions. In: Henry RJ, Cannon DC, Winkleman W, eds. Clinical Chemistry, Principles and Techniques. 2nd ed. Hagerstown: Harper & Row 1974:639-754.
- 7. Data on file at Roche Diagnostics.

#### FOR US CUSTOMERS ONLY: LIMITED WARRANTY

Roche Diagnostics warrants that this product will meet the specifications stated in the labeling when used in accordance with such labeling and will be free from defects in material and workmanship for 90 calendar days from shipment date or from service order date. THIS LIMITED WARRANTY IS IN LIEU OF ANY OTHER WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR PARTICULAR PURPOSE. IN NO EVENT SHALL ROCHE DIAGNOSTICS BE LIABLE FOR INCIDENTAL, INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES.

COBAS INTEGRA, COBAS MIRA, PRECINORM, and PRECIPATH are trademarks of Roche. INTRALIPID is a trademark of Fresenius Kabi AB. FERROZINE is a trademark of Hach Chemical Co., Ames, Iowa, USA. Significant additions or changes are indicated by a change bar in the margin. ©2005 Roche Diagnostics

Roche Diagnostics GmbH, D-68298 Mannheim for USA: US Distributor: Roche Diagnostics, Indianapolis, IN US Customer Technical Support 1-800-428-2336 CE